Altimmune Inc (ALT)

Dec 04, 2025

Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha

Dec 04, 2025

Dec 03, 2025

Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com

Dec 03, 2025

Dec 02, 2025

Durso succeeding Garg as Altimmune CEO - biocentury.com

Dec 02, 2025

Dec 02, 2025

Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat

Dec 02, 2025

Dec 02, 2025

Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review

Dec 02, 2025

Dec 01, 2025

Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail

Dec 01, 2025

Dec 01, 2025

Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView

Dec 01, 2025

Dec 01, 2025

Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals

Dec 01, 2025

Dec 01, 2025

Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada

Dec 01, 2025

Dec 01, 2025

Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com

Dec 01, 2025

Dec 01, 2025

Altimmune, Inc. Announces CEO Changes - marketscreener.com

Dec 01, 2025

Dec 01, 2025

Altimmune CEO Vipin Garg to Step Down - marketscreener.com

Dec 01, 2025

Dec 01, 2025

Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada

Dec 01, 2025

Dec 01, 2025

Altimmune (ALT) Announces CEO Transition Plan - GuruFocus

Dec 01, 2025

Dec 01, 2025

Altimmune falls as CEO Vipin Garg to step down - TradingView

Dec 01, 2025

Dec 01, 2025

Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union

Dec 01, 2025

Dec 01, 2025

Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative

Dec 01, 2025

Dec 01, 2025

Altimmune Announces CEO Transition, Succession Plan - TradingView

Dec 01, 2025

Nov 30, 2025

Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat

Nov 30, 2025

Nov 28, 2025

Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News

Nov 28, 2025

Nov 28, 2025

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 28, 2025

Nov 26, 2025

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times

Nov 26, 2025

Nov 26, 2025

Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan

Nov 26, 2025

Nov 25, 2025

Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN

Nov 25, 2025

Nov 25, 2025

Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT) - MarketBeat

Nov 25, 2025

Nov 24, 2025

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech

Nov 24, 2025

Nov 24, 2025

Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN

Nov 24, 2025

Nov 24, 2025

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - MSN

Nov 24, 2025

Nov 23, 2025

Net debt of Altimmune, Inc. – HAM:3G0 - TradingView

Nov 23, 2025

Nov 22, 2025

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - MSN

Nov 22, 2025

Nov 21, 2025

Will Altimmune Inc. stock outperform international peersJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com

Nov 21, 2025

Nov 21, 2025

While institutions invested in Altimmune, Inc. (NASDAQ:ALT) benefited from last week's 10% gain, individual investors stood to gain the most - simplywall.st

Nov 21, 2025

Nov 21, 2025

How Altimmune Inc. stock benefits from global expansion2025 Big Picture & Verified Entry Point Signals - newser.com

Nov 21, 2025

Nov 21, 2025

How strong is Altimmune Inc. stock revenue growthWeekly Trend Report & Accurate Intraday Trading Signals - newser.com

Nov 21, 2025

Nov 20, 2025

Transcript : Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08 - MarketScreener

Nov 20, 2025

Nov 20, 2025

Altimmune at Jefferies Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com India

Nov 20, 2025

Nov 20, 2025

Will Altimmune Inc. stock reach all time highs in 2025July 2025 Big Picture & Smart Investment Allocation Tips - newser.com

Nov 20, 2025

Nov 20, 2025

Will Altimmune Inc. stock gain from government policies2025 Fundamental Recap & Low Risk Growth Stock Ideas - newser.com

Nov 20, 2025

Nov 19, 2025

Is Altimmune Inc. stock supported by strong fundamentals2025 Trade Ideas & Technical Confirmation Trade Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Using AI based signals to follow Altimmune Inc.Quarterly Risk Review & Free Weekly Watchlist of Top Performers - newser.com

Nov 19, 2025

Nov 18, 2025

What MACD and RSI say about Altimmune Inc.Sell Signal & Accurate Technical Buy Alerts - newser.com

Nov 18, 2025